Does Rallies show Form 4 insider transactions for PLX?

Yes. Rallies tracks PLX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is PLX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for PLX. It does not provide personalized investment advice.

PLX (Protalix BioTherapeutics, Inc. Common Stock) Stock Analysis - Insider Trades

Protalix BioTherapeutics, Inc. Common Stock (PLX) is a publicly traded Healthcare sector company. As of May 21, 2026, PLX trades at $1.94 with a market cap of $153.89M and a P/E ratio of 10.07. PLX moved +5.53% today. Year to date, PLX is +12.29%; over the trailing twelve months it is +16.86%. Its 52-week range spans $0.99 to $3.19. Analyst consensus is buy with an average price target of $12.00. Rallies surfaces PLX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading PLX stock inside the company?

Recent PLX insider activity includes Bashan Dror bought 56.00K, Bar-Shalev Amos sold 168, Schwartz Aharon bought 129.00K, Bashan Dror bought 48.39K, and Bashan Dror bought 16.13K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

PLX Key Metrics

Key financial metrics for PLX
Metric	Value
Price	$1.94
Market Cap	$153.89M
P/E Ratio	10.07
EPS	$0.20
Dividend Yield	0.00%
52-Week High	$3.19
52-Week Low	$0.99
Volume	678.76K
Avg Volume	0
Revenue (TTM)	$76.38M
Net Income	$15.33M
Gross Margin	69.97%

Recent PLX Insider Trades

Bashan Dror bought 56.00K (~$101.36K) on Dec 19, 2025.
Bar-Shalev Amos sold 168 (~$314.16) on Nov 18, 2025.
Schwartz Aharon bought 129.00K (~$205.88K) on Jun 10, 2025.
Bashan Dror bought 48.39K (~$67.74K) on Oct 19, 2023.
Bashan Dror bought 16.13K (~$22.74K) on Oct 19, 2023.

Latest PLX News

Protalix Extends Cash Runway into Late 2027, Completes Phase III Enrollment — May 14, 2026
Protalix Q1 Revenues Fall to $7.4M, Reaffirms $78–$83M 2026 Guidance After $25M Milestone — May 13, 2026
Protalix BioTherapeutics secures €25M after EU dosing approval, forecasts 50% growth — Mar 18, 2026
Protalix wins EU approval for monthly Elfabrio dosing, nets $25M — Mar 18, 2026
Protalix and Chiesi Secure EU Approval for 2mg/kg Every-Four-Weeks Dose, Triggering $25M Payment — Mar 9, 2026

PLX Analyst Consensus

1 analysts cover PLX: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $12.00.

Common questions about PLX

Who is trading PLX stock inside the company?: Recent PLX insider activity includes Bashan Dror bought 56.00K, Bar-Shalev Amos sold 168, Schwartz Aharon bought 129.00K, Bashan Dror bought 48.39K, and Bashan Dror bought 16.13K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for PLX?: Yes. Rallies tracks PLX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is PLX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for PLX. It does not provide personalized investment advice.